Endovia Health Sciences (EDVA) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Feb, 2026Opening remarks and agenda
Meeting called to order by the Chair, held in a virtual-only format with electronic voting and Q&A options for shareholders.
The agenda focused solely on a proposal to amend the Articles of Incorporation to increase authorized common stock from 7.5 million to 400 million shares.
Board and executive committee updates
The Board of Directors unanimously recommended approval of the amendment to increase authorized shares.
Shareholder proposals
The sole proposal was to approve an amendment increasing the number of authorized common shares to 400 million, reversing a prior reduction due to a reverse split.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Endovia Health Sciences
- Shifted to cannabinoid health, posted $2.0M Q2 loss, minimal revenue, and ongoing liquidity risks.EDVA
Q2 2026 - Pivoting to cannabinoid wellness, company seeks capital via equity line amid financial distress.EDVA
Registration filing - Facing liquidity issues, the company pursues a dilutive equity line and entry into the cannabinoid sector.EDVA
Registration filing - Severe revenue decline, liquidity risk, and pending Medterra deal threaten NYSE listing.EDVA
Q1 2026 - Paused operations, major losses, and a planned Medterra CBD acquisition amid severe liquidity risk.EDVA
Q4 2025 - Severe liquidity crisis and no revenue drive urgent capital raise and major dilution risk.EDVA
Registration Filing - Distressed beverage company seeks $35M ELOC, faces dilution and going concern risks.EDVA
Registration Filing - Gross margins improved to 30% as revenue fell and liquidity risks persisted.EDVA
Q3 2024 - Revenue plunged and losses persisted amid liquidity and NYSE compliance risks.EDVA
Q2 2024